Interpace Announces Notice of Allowance from U.S. Patent and Trademark Office Covering BarreGEN®
December 17, 2018 06:50 ET
|
Interpace Diagnostics Group, Inc.
BarreGEN® is Interpace’s Lead Molecular Diagnostic Pipeline Product for Barrett’s Esophagus Parsippany, NJ, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (“Interpace”)...